SINGAPORE O&G LTD.
1D8.SI
Singapore O&G - Slow Start
- Muted growth in 1Q17 impacted by dermatology division, and higher costs.
- Number of births up 10%, market share at 7.4%.
- Growth momentum picking up in cancer division.
- Paediatrics division to commence in July 2017.
Maintain BUY rating, TP of S$0.80 (adjusted for share split).
- We maintain our BUY rating and remain positive on Singapore O&G (SOG)’s growth prospects. Key potential catalysts are:
- better-than-expected growth from its cancer and dermatology divisions,
- expansion into new specialisations such as paediatrics, which is expected to commence in July 2017, and complementary services including in-vitro fertilisation (IVF), imaging or childcare, and
- better-than-expected improvement in margins.
1Q17 growth was muted.
- 1Q17 net profit was up 2.8% y-o-y to S$2m, forming 19% of our FY17F earnings. However, management highlighted that 1Q is typically the weakest quarter. In addition, we have factored in marginal contributions from paediatrics in our FY17 estimates.
- Key positives from the results:
- number of births up 10% y-o-y,
- positive growth momentum in cancer division; and
- expects to commence paediatrics division in July 2017.
- Key negatives:
- revenue of dermatology were flat,
- O&G market share fell marginally to 7.4% (vs 7.5% in FY16),
- EBIT margin deteriorated.
Expanding into higher-margin complementary specialised services.
- Now that paediatrics division will commence soon, management continues to explore new opportunities both in terms of new specialisations and/or new markets. We believe other complementary services to explore include IVF, child care and imaging.
Valuation
- Our target price of S$0.80 (post share split) is based on the average valuation using 30x PE and DCF valuation.
- Our estimates have incorporated marginal contributions from paediatrics division.
Key Risks to Our View
- Key risks that could derail our thesis include
- Execution risks due to lack of track record,
- highly dependent on a few key doctors, and
- low stock liquidity.
WHAT’S NEW
A slow start 1Q17 (typically a weak quarter) growth was muted, partially impacted by dermatology and higher cost.
- Singapore O&G (SOG)’s 1Q17 net profit +2.8% y-o-y to S$2m; 19% of our FY17 estimates. However, management highlighted that 1Q is typically the weakest quarter. In addition, we have factored in marginal contributions from paediatrics in our FY17F earnings.
- Revenue grew 6% y-o-y to S$7m led by O&G (+S$0.3m) and cancer (+S$0.1m) divisions while dermatology division was relatively flat.
- EBIT margin dropped 1.6ppts to 34.2%, largely due to higher staff costs (+11%) from higher headcount (9 additional staff) of which 2 are specialist medical practitioners, and accrual of staff bonuses, which are now made every quarter (c. S$0.5m), lower government grants of S$37k from S$102k, and higher depreciation (55%).
- We note that higher fees of S$115k were recognised in 1Q16 for the acquisition of Dr Joyce Lim’s clinics, and excluding this, EBIT margin would have dropped by 3.3 ppts.
O&G division: Delivered 404 births (+10% y-o-y); market share fell marginally to 7.4%.
- Despite the number of national births falling 1% y-o-y, possibly due to the Zika virus scare in 1Q16, SOG delivered 404 births in 1Q17 (+10% y-o-y) but market share fell marginally to 7.4% from 7.5% in FY16.
Cancer division: Growth momentum picking-up.
- Revenue from the cancer division achieved positive growth with management continuing to see growth momentum picking-up further for the cancer division.
- Dermatology division: Despite the strong FY16 results driven by the dermatology division, 1Q17 is typically a weak quarter.
Paediatrics division: On 5 Apr 2017, SOG announced the incorporation of SOG Children (Paediatrics) Pte Ltd.
- Management expects that the new division will commence in July 17 with at least 1 new paediatrician on board.
Rachel TAN
DBS Vickers
|
Andy SIM CFA
DBS Vickers
|
http://www.dbsvickers.com/
2017-05-15
DBS Vickers
SGX Stock
Analyst Report
0.80
Same
0.80
